BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 18, Issue 1
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis
©The Author(s) 2026.
World J Gastrointest Oncol. Jan 15, 2026; 18(1): 113816
Published online Jan 15, 2026. doi: 10.4251/wjgo.v18.i1.113816
Figure 6
Full Size Figure Download Figure
Figure 6 Forest plot of disease control rate comparing regorafenib and control therapies. Using a fixed-effects model (I2 = 0.0%), the pooled analysis indicated no statistically significant difference in disease control rate between treatment groups (odds ratio = 1.09; 95% confidence interval: 0.81-1.45; P > 0.05), suggesting comparable disease stabilization efficacy. CI: Confidence interval.
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.